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Summary The lymphocytes from lymph nodes of six patients with metastatic mammary carcinomas were
hybridised by fusion with a non-secreting variant of murine myeloma cells. Hybrid cells producing human
immunoglobulin were detected by screening of culture supernatants using a solid-phase enzyme-linked
immunosorbent assay for human IgG or IgM. Reactivity of human immunoglobulins to breast tumour cells
was assessed by an indirect immunoperoxidase staining of fresh-frozen breast carcinoma sections. In the
initial screening, the tissues used were those removed from the patients who acted as source of lymphocytes
for fusion. The hybrid-cells, after repeated cloning, were stable for secretion of immunoglobulins. A total of
14 immunoglobulin G and 51 immunoglobulin M human monoclonal antibodies, showing variable reactivity
to mammary carcinoma cells in tissue sections by an indirect immunoperoxidase staining method, were
obtained. Two immunoglobulin G monoclonal antibodies (designated HMA-29 and HMA-31) were selected
on the basis of their strong reactivity to the tumour cells and utilised to identify their corresponding antigens.
The antibodies quantitatively discriminated, as expressed by the degree of staining, malignant from normal or
benign mammary epithelia in freshly frozen or formalin-fixed breast tissues. The antibodies also showed
reactivity to malignant cells of colon, stomach and lung and to normal cells lining the renal tubules and
surface epithelium of colon. As revealed by blocking experiments, the epitopes recognised by these antibodies
were not expressed on carcinoembryonic antigens, erythrocytes, lymphocytes, glycoproteins from milk-fat-
globule membrane or keratins. The antibody HMA-29 immunoprecipitated a phosphoprotein (Mr=29,000),
and antibody HMA-31 two protein components (Mr=31,000 and 34,000), from lysates of intrinsically labelled
human mammary carcinoma cell line (MCF7). Neither of these proteins were present in detectable amounts in
an intrinsically labelled melanoma cell line. Immunoblocking and immunoprecipitation experiments suggested
that epitopes recognised by these two antibodies are dissimilar and are expressed on different molecules. The
antibodies appear to be useful for functional characterisation of those antigens which are present in elevated
levels in malignant compared with normal mammary epithelia.
The evidence for the presence of mammary carcinoma-
associated antigens has been reported (Howard & Taylor,
1979; Springer et al., 1979; Sheiks et al., 1979). Conversely,
antibodies present in the serum of patients with mammary
carcinoma have also been shown to be reactive with the
carcinoma cells (Colcher et al., 1981; Soule et al., 1983).
Accordingly, attempts have been made to utilise lymphocytes
from patients with metastatic malignant diseases to produce
human monoclonal antibodies by the hybridoma technique
(Cote et al., 1983; Haspel et al., 1985; Imam et al., 1985;
Low et al., 1984; Schlom et al., 1980; Sikora et al., 1981). In
order to generate such human antibodies, lymphocytes were
taken from the draining lymph nodes of patients with
metastatic mammary carcinoma and fused with non-
secretory variant of mouse myeloma cells to obtain human
immunoglobulin secreting hybrids.
This paper reports the generation and application of
human monoclonal antibodies as probes to identify and
characterise antigens which are present at elevated levels in
malignant compared with normal mammary epithelia.
Materials and methods
Materials
Aminopterin, thymidine and hypoxanthine were obtained
from Sigma Chemicals (St Louis, MO, USA) and
polyethylene glycol 1500 from Aldrich Chemical Co.
(Milwaukee, WI, USA). Chromatographically purified
human IgM and IgG, rabbit antihuman IgM (M-chain
specific), rabbit antihuman IgG (gamma-chain specific),
F(ab)'2 fragment of goat antihuman Fab, rabbit antihuman
kappa and lambda light chains, mouse IgG and IgM and
sheep antimouse immunoglobulins with no cross reactivity to
human immunoglobulins were the products of Cappel
Laboratories. Tissue culture reagents were purchased from
Flow Laboratories CA, USA) and a gamma horse serum
from Bio-Cells Laboratory (Carson, CA, USA).
Cellfusion and cloning
Portions of axillary lymph nodes from patients with
metastatic breast carcinoma were obtained and processed as
described previously in order to obtain live human
lymphocytes in suspension (Imam et al., 1985). The
lymphocytes and mouse myeloma cells (M5, a non-secreting
and horse serum adapted subline of SP2/OAg 14) were
mixed at a ratio of 2.5 to 1, respectively, and fused using
34% (v/v) polyethylene glycol (mol. wt 1,500 daltons) as
described previously (Imam et al., 1985). The hybrid cells
secreting human immunoglobulin with reactivity to breast
carcinoma cells in tissue sections were cloned by limiting
dilution. Using this procedure, cloning efficiency varied from
29 to 54% (average 44%).
Spent-media from wells containing hybrid-cells were
assayed for the presence of human IgG or IgM by solid
phase enzyme-linked immunosorbent assay (ELISA) as
described previously (Imam et al., 1985).
Production and purification of human monoclonal antibodies
The human-mouse hybrid clones, designated as HMA-29
(IgG1 antibody), HMA-31 (IgG2 antibody), selected on the
basis of production of antibodies with strong reactivity to
mammary carcinoma cells in tissue sections, were injected
intraperitoneally into Balb/C nude mice which had been
primed with pristane 3 weeks earlier. Two to three weeks
later, ascites fluid was harvested from the mice and clarified
by centrifugation at 12,000g and 4°C for 15min. The
immunoglobulin from ascites fluid was purified as described
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previously (Imam et al., 1985). The purified antibodies were
conjugated with biotinyl-N-hydroxysuccinimide ester as
described previously (Imam et al., 1985).
Preparation of tissue sections
Uninvolved and malignant human tissues were obtained
from the surgical pathology files of the University of
Southern California/Los Angeles County Medical Center.
Tissues used were either frozen in liquid nitrogen or fixed in
10% buffered-formalin. The fixed paraffin embedded tissue
was sectioned at 5,um in thickness. Representative tissue-
sections were stained with Haematoxylin and Eosin to
confirm the diagnosis before immunoperoxidase staining.
Comparison of epitopes recognised by human MAbs
To determine whether the presently generated two antibodies
and those generated previously, termed CA-27 (25) and JD-
39 (22) (Imam et al., 1985), recognise similar or different
epitopes, blocking assays using immunohistological
techniques were performed as described previously (Imam et
al., 1985). The antibodies CA-27 (25) or JD-39 (22) were
generated previously in a similar manner. The ability of
these antibodies to discriminate malignant from normal cells
in breast tissues was not as significant as those presently
prepared, HMA-29 and HMA-31.
Immunocytochemical localisation of tissue antigens
The four-layer unlabelled antibody peroxidase-
antiperoxidase, PAP, and an avidin-biotin-peroxidase
complex, ABC, methods were used for localising tissue
antigens with the human monoclonal antibodies (Imam &
Taylor, 1985).
PAP method of staining
This method of staining was employed during the initial
period of screening. Human monoclonal antibodies produced
by hybrids in tissue-culture-medium were tested for their
ability to bind to antigens in histological sections of breast
tissue. The tumour tissues used in the primary screening were
obtained from the patients who acted as sources of
lymphocytes for fusion. Rabbit antihuman IgG or IgM and
swine antirabbit antibody were used as the 'link' or 'bridge
antibodies' between the human monoclonal antibody
(primary) and rabbit peroxidase-antiperoxidase (PAP)
complex. Controls included the replacement of primary
antibody by an irrelevant human monoclonal antibody to
Hodgkin's cells. (Antibody secreted by hybrid that was
obtained by fusing mouse myeloma cells with lymphocytes of
lymph node from patients with Hodgkin's disease. The
antibody showed strong reactivity with Reed-Stemnberg cell
(manuscipt in preparation).) The tissue sections were
incubated with each antibody in an appropriate dilution for
60min at room temperature. Following each incubation
period, the sections were washed with PBS for 15min. The
remainder of the procedures was as described previously
(Imam et al., 1985).
The ABC method of staining
Biotinylated human monoclonal antibodies (104gml 1) were
applied directly to tissue sections. Following the washing of
the tissue sections with PBS, avidin-biotin-peroxidase
complex in dilution according to vendor's instructions was
added. Biotinylated specific antibodies preincubated with an
extract of mammary carcinoma cell line, MCF7, or a
biotinylated irrelevant human monoclonal antibody to
Hodgkin's cells, replacing the same amounts of specific
antibody, served as negative controls. Histological
classification of mammary epithelial cells was determined
according to Bloom & Richardson (1975). The visual
estimates of staining intensities were graded as: (-) absent,
(±) borderline, (1+) weak, (2+) moderate, (3+) intense. To
account for case to case variation in the degree of intensity
of staining, any given tumour specimen was evaluated
relative to a 'positive control' tissue section containing
infiltrating ductal carcinoma cells (and also adjacent normal
breast ducts with virtually no reactivity). Visual estimates of
the percentage of cells showing reactivity were determined by
examining at high magnification (400 x) five random fields
in every tissue section. The mean of counts from the fields
examined was recorded as the percentage of cells with
staining.
Absorption of biotinylated human monoclonal antibodies with
known antigens
The biotinylated antibodies, HMA-29 or HMA-31
(1 mgml-1) were separately incubated overnight at 4°C with
1Omg protein preparation from human erythrocytes, lym-
phocyte, milk-fat-globule membrane (Imam et al., 1981,
1982), keratins (Sun & Green, 1978), the detergent extract of
unlabelled MCF7 cell lysates, mammary carcinoma tissue or
1 mg of carcinoembryonic antigen (CEA) immobilised to
Sepharose 4B. The procedure of preparing the extract of
unlabelled cell lysate was the same as described below for the
metabolically labelled cells. Following incubation, the solu-
tions were centrifuged at l00,OOOg and 4°C for 30min. The
supernatants containing absorbed antibodies were removed
and subsequently applied to tissue sections for immunostain-
ing analysis.
Characterisation of the epitope recognised by human MAbs
Investigation was conducted to determine whether the
human monoclonal antibodies were directed to the protein
and/or the carbohydrate portion of antigens recognised by
the antibodies as described below.
Treatment with endo-f3-N-acetylglycosaminidase H
To monitor the cleavage of antigens recognised by HMA-29
or HMA-31 with endo-fl-N-acetylglucosaminidase H, 0.25pg
protein of MCF7 cell line extract in I00pl of 0.1 M sodium
citrate buffer, pH5.5, containing 50mu of the enzyme were
incubated at 37°C for 18h as described by Tarentino et al.
(1974). Following incubation, the reaction mixture was
mixed with an equal volume of cold 12.5% (w/v) trichloroa-
cetic acid (TCA) for 15min at 4°C. The mixture was
centrifuged at 12,000g and 4°C for 15min, and the superna-
tant was removed and dialysed against several changes of
PBS at 4°C. The pellet was dissolved in 100!l of PBS and
dialysed. To ensure a complete precipitation, an appropriate
control containing only the antigen in the absence of the
enzyme was included.
Treatment with pepsin
Two hundred and fifty micrograms of protein from MCF7
cell line extract was dissolved in 100I 1 of 0.07M sodium
acetate buffer, pH4.0, containing 0.05MNaCl and 15jg of
pepsin, and the reaction mixture was incubated at 37°C in a
water-bath for 18h. At the end of the enzymic digestion
period, the pH of the solution was adjusted to 8 with
1 NNaOH and was dialysed against several changes of PBS.
Metabolic labelling of cells and preparation of cell lysate
Mammary carcinoma cell line, MCF7, and melanoma cell
line, M17, were grown as monolayer cultures in 75mm2
tissue culture flasks and intrinsically labelled when cultures
were still subconfluent. The cells were labelled for 24-48h
with either 2mCi of 3H-leucine (110Cimmol-1) or 10mCi
of 32P-phosphate (carrier-free) per flask of leucine or
phosphate-free DME medium respectively. Following incu-
bation, the cells were washed three times and lysed with
0.05M Tris-HCl buffer, pH 7.5, containing 0.15M NaCl,
0.5% (v/v) Nonidet P-40 (NP-40), 0.5% (w/v) sodium deoxy-924 A. IMAM & C.R. TAYLOR
cholate, 1 mM phenylmethylsulphonyl fluoride and 0.5 mM
chloromethyl-L-(2-phenyl-l-p-toluenesulphosnamide) ethyl
ketone on ice for 15min. The lysates were centrifuged at
40,000g and 4°C for 20min. The supernatants containing
detergent-solubilised materials were subsequently used for
immunoprecipitation.
Immunoprecipitation of extracts of radiolabelled cells with
human monoclonal antibodies
The radiolabelled cell lysates (approximately 400 ng of pro-
tein containing 5 x 107 c.p.m.) were mixed with 100 p1 of
either a specific human MAb (1.Omgml-1) or an irrelevant
human MAb generated by fusing lymphocytes from patients
with Hodgkin's disease. The latter antibody served as a
negative control. The mixtures were incubated at 4°C for
16h. Following the incubation, a 100I 1 suspension of
Sepharose 4B conjugated to goat antihuman IgG as de-
scribed above was added to each reaction mixture. The
samples were incubated for a further period of 60min and
centrifuged at 5,000g for 5 min. Following the removal of
supernatant by aspiration, the pellet was washed five times
with 0.05 MNaCl, 1.0% (w/v) ovalbumin and 0.2% (v/v)
NP-40 to remove any non-specifically bound radioactivity.
No radioactivity was detectable in the supernatant of the
fifth wash.
SDS-Polyacrylamide gel electrophoresis
The materials immunoprecipitated with the human MAbs
were subsequently analysed by SDS-polyacrylamide gel elec-
trophoresis. The washed pellets were solubilised in 0.05M
Tris-HCI buffer, pH6.8, containing SDS and 2-
mercaptoethanol, boiled for 5min and centrifuged at 8,000g
for 5min at room temperature. The supernatants were
subjected to electrophoresis in 7.5% polyacrylamide slab gels
in the presence of SDS by the method of Laemmli (1970). A
constant current of 30mA was applied to each gel for 3-4h
until the dye front approached to within 1 cm of the bottom.
The gels were then fixed and stained with 0.25% (w/v)
Coomassie blue in a solution containing 50% (v/v) isopropyl
alcohol and 10% (v/v) glacial acetic acid. Destaining was
performed in a solution containing 10% (v/v) isopropyl
alcohol and 10%(v/v) glacial acetic acid. The destained gels
were treated with 'Enhance' (New England Nuclear, Boston,
MA, USA) and dried on a Whatman no. 3 MM filter paper
under reduced pressure, and the radioactive components
were visualised by fluorography.
Results
Generation and cloning of human-mouse hybrid cells
Fourteen IgG and 51 IgM producing stable hybridomas were
obtained. The hybridomas were obtained by fusing lympho-
cytes (obtained from the regional lymph nodes of six differ-
ent patients with metastatic mammary carcinoma) with a
non-secretory variant of mouse myeloma cell line (M5, a
horse serum-adapted subline of SP2/OAg 14) (Tables I
and II).
Screening assay for the presence of human immunoglobulins
The enzyme-linked immunoabsorbent assays (ELISA) were
employed for the detection of human IgG or IgM secreted
by the hybrid-cells in spent media. The specificity and
sensitivity of the assays for human IgG or IgM. The
sensitivity of the assay was 0.12 pgml-1 for the detection of
IgG or IgM. The assay was specific to its corresponding
antigen within the range of 0.03-5.0 pgml- 1 of detection. No
cross-reactivity between human and mouse immunoglobulins
in this range of detection was observed. Furthermore, human
IgG and IgM showed no cross-reactivity in the assay. On
average, 32% of the wells containing hybrid-cells were
Table I Generation of human-mouse hybrids that
secreted human immunoglobulins
No. of wells
with hybrids
No.. of wells No. of wells producing
Fusion seeded with hybrids human Iga
1 94 39 19b
2 243 123 21b
3 138 61 32b
4 176 82 27b
5 45 28 Ilb
6 116 57 16b
Total 812 390 (48%) 126 (32%)
aNumber of wells with growing hybrids with
>0.5yg immunoglobulin per ml of spent medium.
bFollowing immunohistological screening for specifi-
city, hydrids from one of each of these wells were
selected and cloned (see Table II).
Table II Secretion and binding reactivity of human monocloncal
antibodies produced by cloned hybrids
No. ofhybrid
clones producing
antibodies with
Wells with No. of hybrid reactivity to
single clone clones with breast tumour
after cloning human cells
Fusion of Ig positive
no.a hybrids IgG IgM IgG IgM
1 97 (45%) 9 21 3 8
2 56 (29%) 2 17 1 11
3 86 (45%) 29 6 7 4
4 71 (37%) 7 8 1 3
5 89 (46%) 0 23 - 16
6 104 (54%) 5 19 2 9
Total 503 (44%) 52 (10%)94 (19%)14 (27%)51 (54%)
aHybrids from six immunoglobulin positive wells (see Table I and
column 4, one from each fusion) were selected, cloned and plated
into two 96-well plates. The parameters of selection for cloning of
hybrids were based upon their ability to secrete higher amounts of
Ig with strong reactivity to tumour cells in tissue sections more than
the Ig produced by the remaining hybrids.
obtained from lymphocytes from patients with metastatic
breast carcinomas synthesised human immunoglobulins
(Table I). Hybrids from six immunoglobulin positive wells,
one deriving from each fusion (Table I, column 4), were
selected, cloned and plated into two 96-well plates. The
parameters of selection for cloning of hybrids were based
upon their ability to secrete higher amounts of Ig with
strong reactivity to tumour in comparison with normal
mammary epithelial cells in frozen tissue sections. An in-
direct immunoperoxidase technique of screening for Ig bind-
ing, as described in the Methods section, was employed.
Fifty-two IgG and 94 IgM monoclonal antibodies producing
clones were obtained (Table II). Of these antibodies, 14IgG
(27%) and 51 IgM (54%) showed evidence of reactivity to
tumour cells as described above (Table II). The levels of
human immunoglobulin produced by cloned hybrids varied
from 0.5 to 2.0pg of IgG or 2.5 to 5.0Mg of IgM per ml of
spent medium. The human MAbs in ascites yielded human
IgG or IgM within a range of 2-4mgml-1. For accurate
determination of the concentration of affinity purified IgG
monoclonal antibodies, their corresponding purified isotypes
of human IgG (i.e. IgG1, IgG2, IgG3, IgG4) were used as
standards in ELISA.
The majority of interspecies hybrids were not stable for
producing human immunoglobulins. However, an early clon-
ing (post-fusion days 25-30), and repeated cloning (post-
cloning days 40-60 and 110-120), of the positive hybrids
appears to enhance their stability in continuing to produce
immunoglobulins.ANTIGENS RECOGNISED BY HUMAN MAb 925
Table III Determination of epitopes recognised by human monoclonal antibodies by an immunohistological
technique
Intensity of
staining
of mammary
Incubated Incubated Incubated Incubated carcinoma
with Wash with with Wash with with Wash with with cellsc
PBS PBS HMA-29d PBS ABCa PBS AEC-H202b 3+
HMA-29c PBS HMA-29d PBS ABCa PBS AEC-H202b -
HMA-31e PBS HMA-29d PBS ABCa PBS AEC-H202b 3+
PBS PBS HMA-3ld PBS ABCa PBS AEC-H202b 3+
HMA-31e PBS HMA-3Id PBS ABCa PBS AEC-H202b -
HMA-29e PBS HMA-3ld PBS ABCa PBS AEC-H202b 3+
PBS PBS CA27(25)d,f PBS ABCa PBS AEC-H202b 3+
CA27(25)ecf PBS CA27(25)d.f PBS ABCa PBS AEC-H202b -
HMA-29e PBS CA27(25)df PBS ABCa PBS AEC-H202b 3+
HMA-31e PBS CA27(25)d,f PBS ABCa PBS AEC-H202b 3+
PBS PBS JD39(22)df PBS ABCa PBS AEC-H202b 3+
JD39(22)e,f PBS JD39(22)d.f PBS ABCa PBS AEC-H202b -
HMA-29e PBS JD39(22)df PBS ABCa PBS AEC-H202b 3+
HMA-31e PBS JD39(22)df PBS ABCa PBS AEC-H202b 3+
aAvidin-biotin-peroxidase complex (ABC); baminoethyl carbazole-hydrogen peroxide; cabsence of staining -
intense staining 3+; dbiotinylated human monoclonal antibody; cunlabelled human monoclonal antibody;
fImam et al. (1985).
Comparison of epitopes recognised by human monoclonal
antibodies
The experiments were performed to determine any similarity
between epitopes recognised by presently generated human
monoclonal antibodies (HMA-29, HMA-31) and previously
generated antibodies (CA-27 (25) or JD-39 (22)) (Imam et
al., 1985). The immunoblocking experiments showed that the
antigenic binding sites for antibody HMA-29 were not
blocked by antibody HMA-31. Conversely, the reactivity of
HMA-31 was not obstructed by antibody HMA-29 (Table
III). Indeed, the antigens recognised by these antibodies are
also different with respect to their molecular weights (Figure
2, lanes a, b). Furthermore, the binding activity of HMA-29
and HMA-31 was not blocked by any of the previously
generated antibodies CA-27 (25) or JD-39 (22) (Table III).
The results indicate that two different epitopes are recog-
nised by the antibodies and are not related to epitopes
recognised by previously generated antibodies.
Localisation of cellular antigens with human monoclonal
antibodies
Spent medium from each of the immunoglobulin-producing
clones was initially screened for binding activity to tissue
sections of autologous breast carcinoma using an indirect
immunoperoxidase (PAP) staining technique. The indirect
four-layer PAP methods gave some background staining,
attributable to detection of endogenous IgM or IgG in
breast tissues. Endogenous immunoglobulin sensitivity was
more notable while staining for human monoclonal anti-
bodies of IgG class, but did not interefere with the inter-
pretation of staining patterns, which in all cases were
assessed with reference to positive and negative controls as
described in the methods section. The findings are summar-
ised in Table II (columns 5, 6).
Fourteen IgG and 51 IgM human MAbs showed staining
of tumour cells with a variable intensity in all cases of
infiltrating ductal carcinoma of the breast (Table II). Under
these conditions, lymphocytes, blood vessels and stromal
elements failed to stain. Weak staining of morphologically
normal breast epithelial cells present in the same tissue
section was observed in some cases. However, the intensity
of staining in such cases was much less than for malignant
cells (Figure la).
Of these 65MAbs, two antibodies designated HMA-29
(IgG1 antibody) and HMA-31 (IgG2 antibody), were selected
for further study. The chief parameter for selection rested
a-
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Figure 1 Binding pattern of a human monoclonal antibody
HMA-29 to mammary epithelial cells in formalin-fixed and
paraffin-embedded tissue sections by a direct immunoperoxidase
(avidin-biotin-peroxidase) method. The biotinylated human
monoclonal antibody was applied at a concentration of
l0pgml- . The sections were counterstained with Mayer's hae-
matoxylin. The stromal components were consistently negative.
(a) Normal and infiltrating ductal carcinoma of breast. The
uninvolved duct at the lower left side (short arrow) is virtually
unstained whereas surrounding malignant cells (long arrow)
showed strong reactivity of cytoplasmic components with the
antibody (original mag. x 150). (b) Infiltrating ductal carcinoma.
Not all tumour cells in certain cases showed reactivity (absence
of staining is indicated by short arrow), indicating antigenic
heterogeneity among the tumour cell population (original mag.
x312).926 A. IMAM & C.R. TAYLOR
Table IV Study of the binding patterns of human monoclonal antibodies HMA-29 and HMA-31
to cellular antigens in buffered formalin-fixed and paraffin embedded tissue sections by an
immunoperoxidase method
HMA-29 HMA-31
No. of % cell % cell
case Intensity stained Intensity stained
Breast tissue
Lactating breast 2 -(2/2) 0 -(2/2) 0
Morphologically uninvolved breast 3 +(3/3) 30 +(3/3) 30
Fibroadenoma 3 1 +(2/3) 25 1 +(2/3) 30
Infiltrating ductal carcinoma 35 3+(31/35) 70 3+(34/35) 80
Lobular carcinoma 6 2+(4/6) 80 2+(3/6) 70
Medullary carcinoma 3 2+(2/3) 75 2+(3/3) 70
Metastatic infiltrating ductal
carcinoma in axillary lymph nodes 5 2+(4/5) 86 2+(4/5) 90
Other tissue
Colon normal 3 1+(2/3) 60 +(2/3) 50
Colon carcinoma 3 2+(3/3) 80 1+(2/3) 65
Kidney normal 3 1+(3/3) 90 1+(3/3) 90
Kidney carcinoma 3 -(3/3) 0 -(3/3) 0
Lung normal 3 -(3/3) 0 -(3/3) 0
Lung carcinoma 3 1+(1/3) 30 +(3/3) 40
Normal skin 3 -(3/3) 0 -(3/3) 0
Malignant cutaneous melanoma 3 -(3/3) 0 (3/3) 0
Pancreas normal 2 -(2/2) 0 -(2/2) 0
Pancreas carcinoma 3 -(3/3) 0 -(3/3) 0
Salivary gland normal 2 -(2/2) 0 -(2/2) 0
Stomach normal 2 0(2/2) 0 0(22) 0
Stomach carcinoma 3 2+(3/3) 60 1+(2/3) 50
upon their ability to stain tumour cells more intensely than
the remaining 63 antibodies. Subsequently, those two anti-
bodies were generated in large amounts, purified and bio-
tinylated as described under Materials and methods. The
intensity and pattern of staining with these conjugated
antibodies of the tumour cells in tissue sections using the
avidin-biotin (ABC) method was comparable to that of the
four-layer PAP method used in the initial stage of the
screening. However, the most distinct and significant advan-
tage gained by the direct ABC method over the PAP method
was the elimination of background staining (i.e. endogenous
immunoglobulin was not detected by the direct ABC
method). The staining results of a panel of paraffin sections
that included 44 cases of primary mammary carcinomas,
three cases of fibroadenoma, three cases of morphologically
uninvolved breast, two cases of lactating breast and five
cases of metastatic mammary carcinoma cells in regional
axillary lymph nodes are summarised in Table IV. Antibody
HMA-29 and HMA-31 showed variable staining of tumour
cells in 84% and 77% of the primary and the regional
metastatic mammary carcinomas respectively. The antigenic
heterogeneity of malignant cells was observed (Figure lb).
The lymphocytes and connective tissue elements in the breast
section, and lymphocytes in ly'mph nodes, were unreactive
with the antibodies. Both antibodies showed variable re-
activity with malignant epithelial cells of colon, stomach and
lung (Table IV). The antibodies quantitatively discriminated
malignant from normal cells in mammary and extramam-
mary tissue sections whether freshly frozen or formalin-fixed.
Control sections in which the monoclonal antibodies were
replaced by equivalent amounts of human IgG or IgM (in
the case of the four-layer PAP method during initial screen-
ing of the antibodies) or an irrelevant biotinylated human
monoclonal antibody (generated in a similar manner to
Hodgkin's cells in the subsequent studies) showed no
staining.
Comparison with known antigens
Both antibodies, HMA-29 and HMA-31, showed no change
in their pattern of reactivity with the cells in tissue sections
following adsorption with carcinoembryonic antigen (CEA),
erythrocyte, lymphocyte, milk-fat-globule membrane
(MFGM) or keratins, suggesting that the epitopes recognised
by these antibodies are dissimilar to those present in the
absorbents. By contrast, absorption of the antibodies with
detergent extracts of MCF7 cell lysate and mammary carci-
noma tissue completely abolished staining of tumour cells in
tissue sections, attesting to the specificity of the reaction.
The nature of epitopes recognised by human monoclonal
antibodies
The antibodies absorbed with TCA-precipitable fraction,
resulting from treatment of the antigens with endo-f,-N-
acetylglucosaminidase H, led to a complete elimination of
immunostaining of cells. The absorption of the antibodies
with the TCA-soluble fraction of the endoglycosidase-
treatment (supernatants) or TCA-precipitable fractions from
pepsin treatment of the antigen had no effect on the intensity
of the immunostaining. The results suggest that the anti-
bodies recognised epitopes which are expressed on the
protein domain of their corresponding antigen.
Immunoprecipitation and electrophoretic analysis of
radiolabelled antigens recognised by human MAbs
3H-Leucine or 32P-phosphate labelled cells from a mammary
carcinoma cell line (MCF7) and a cutaneous malignant
melanoma cell line (M17) were used to study the nature and
range of expression of antigens recognised by human MAbs.
The immunoprecipitation experiments, using the NP 40-
deoxycholate solubilised lysates of intrinsically labelled com-
ponents of MCF7, revealed that the antigens recognised by
antibodies HMA-29 and HMA-31 represented 0.008% and
0.01% respectively of the total lysate. The results suggest
that the target antigens are minor components of the MCF7
cell line. Autoradiographical analysis of 3H-leucine labelled
MCF7 lysate on SDS-polyacrylamide gel electrophoresis
showed one component with HMA-29 with an apparent
molecular weight of 29,000 daltons and two components
with HMA-31, with apparent molecular weights of 31,000
and 34,000 daltons (Figure 2, lanes a, b). Furthermore,
immunoprecipitation of 32P-labelled MCF7 lysate and
HMA-29 yielded a component that migrated to the same
position on the gel as did the 3H-leucine labelled 29,000ANTIGENS RECOGNISED BY HUMAN MAb 927
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Figure 2 Sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis analysis of components immunoprecipitated by human
monoclonal antibody designated HMA-29 (lanes a and d),
HMA-31 (lanes b and e) and LYM 12.29 (lanes c and f) of
lysates from 3H-leucine labelled mammary carcinoma cell line,
MCF7 lysates (lanes a-c), or melanoma cell line, M.17 (lanes d-
f). In addition, lysates from 32p phosphate labelled MCF7 were
immunoprecipitated by HMA-29 (lane g), HMA-31 (lane h) and
LYM 12.29 (lane i). Molecular weight standards were myosin
(200kd), ,B-galactosidase (116kd), phosphorylase B (93 kd),
bovine serum albumin (66kd), ovalbumin (45 kd), carbonic
anhydrase (31 kd) and soybean trypsin inhibitor (21 kd) and their
positions are indicated on the left.
component (Figure 2, lanes a, g). The antibody HMA-31
failed to immunoprecipitate any detectable component from
32P-labelled MCF7 lysate (Figure 2, lane h), and none of the
antibodies gave detectable immunoprecipitation with lysates
of 3H-leucine labelled melanoma cells (Figure 2, lanes d, e).
Conversely, cell lysates of both the mammary and melanoma
cell lines were non-reactive with an irrelevant human MAb
that wasgenerated to Hodgkin's disease (Figure 2, lanes c, f, i).
To investigate the structural relationship of the 29, 31 and
34 kilodalton protein components, 3H-leucine or 32P-
phosphate labelled immunoprecipitates were analysed under
both non-reducing and reducing conditions by SDS-
polyacrylamide gel electrophoresis. Under both conditions,
patterns of migration of these components remained similar,
suggesting the absence of disulphide bonds between these
molecules (data not shown).
Discussion
This study has shown that human-mouse hybridomas can be
obtained by fusing murine myeloma cells with lymphocytes
from the lymph nodes of patients with metastatic mammary
carcinomas. The inter-species hybrids were initially unstable
for immunoglobulin production, but could be made stable in
culture by the following manoeuvres. Repeated cloning
formed a separation of immunoglobulin secreting hybrids
from non-secreting hybrids: the removal of non-secretory
hybrids appears to be crucial as they tend to proliferate at a
higher rate and eventually overgrow those hybrids actively
secreting immunoglobulins. In order to detect the develop-
ment of non-secreting hybrids, the level of immunoglobulin
production was constantly monitored, and when any
decrease was detected, the hybrids were immediately re-
cloned. The hybrid clones were frozen in several aliquots,
and were thawed and propagated for 2-3 weeks when
needed. Sufficient numbers of hybrid cells were obtained for
injection into nude mice in order to generate large amounts
of human monoclonal antibodies in ascites-fluid. Taking into
consideration all these factors, one can successfully obtain
inter-species hybrids that are stable in continuing to secrete
human immunoglobulins.
Anticipating the presence of only small amounts of human
MAbs in spent medium, an indirect four-layered peroxidase-
antiperoxidase (PAP) method (Narikito & Taylor, 1982) was
adopted for the screening of supernatants for the presence of
antibody with specific reactivity to breast carcinoma cells in
fresh-frozen tissue sections. One disadvantage of this
approach was that the indirect staining method would detect
not only the specific binding of human MAb, but also the
presence of any endogenous human immunoglobulin in the
section. To overcome this difficulty, the concentration of the
anti-human Ig antibody used in the PAP method was
empirically titrated for each individual tissue to minimise
background stainings. Such an exercise was paramount as
the amounts of endogenous Ig varied in tissues from differ-
ent patients. Owing to a lesser amount of endogenous IgM
present in breast tissues, interpretation of immunostaining by
human monoclonal antibodies of IgM was easier when
compared with IgG class. With these reservations, this
indirect immunohistological approach was found to be
adequate for the initial screening of the supernatants, as
demonstrated by the identification of hybrids secreting anti-
bodies that reacted with malignant mammary epithelial cells.
One significant advantage of immunohistological screening
over other methods is that it provides information not only
of positivity against a particular cell type, but also of
specificity, in that differential staining of the various cell
types present in the test sections may be observed. This
permits elimination of those antibodies which react with
many cells or tissue elements. For further tests of specificity
and patterns of reactivity of the selected human MAbs
against a variety of tissue specimens, a direct immunoperoxi-
dase method was adopted, utilising biotinylated primary
antibody and avidin-biotin-peroxidase complex (ABC)
system. This direct approach eliminates the detection of
endogenous human immunoglobulin, without compromising
detection of binding of the human MAbs to tissue antigens.
However, direct biotinylation is not feasible for use in the
initial screening of supernatants due to the sheer number of
wells that must be assayed.
Both antibodies (designated HMA-29 and HMA-31) in a
range of 0.2-2pgml- per tissue section showed strong
binding with malignant and very weak binding with normal
mammary epithelial cells in both frozen or formalin-fixed
tissue sections (Figure 1). Reactivity of both antibodies
appeared to be mostly cytoplasmic at the light microscopical
level. The immunoelectron microscopical examination may
facilitate the specific localisation of the target antigens. Low
intensity of staining of normal mammary epithelial cells was
also observed, suggesting the presence of smaller amounts of
antigen(s) in normal cells. The intensity of the staining in
such instances was much weaker than that observed with
malignant cells. Approximately 70-80% of the malignant
cells in frozen or formalin-fixed tissue sections at their
primary sites in any given tissue section showed reactivity
with the antibodies, suggesting antigenic heterogeneity in the
population of primary tumour cells (Table IV).
The antigens detected by antibodies HMA-29 and HMA-
31 were not unique to mammary epithelial cells as revealed
by the reactivity of these antibodies with malignant epithelial
cells of colon, stomach and lung. However, the demon-
stration of tissue antigens by immunostaining yields little
indication of the nature of the antigens in these different
sites. Therefore, isolation and biochemical characterisation of
target antigens from the above sources warrants subsequent
studies.
The immunoprecipitation experiments revealed that the
antigens recognised by the antibodies represent minor consti-
tuents of MCF7 cell line. Consequently, the use of cell
lysates containing high radioactive counts became essential
in visualising the target antigens. As a result, the goat928 A. IMAM & C.R. TAYLOR
antihuman IgG antibodies, which were used as the second
antibodies during the immunoprecipitation, were immobi-
lised to bisoxirane instead of cyanogen bromide-activated
Sepharose 4B as the former yields less non-specific absorp-
tion of proteins (Murphy et al., 1976; Sundberg, 1974). Two
protein components immunoprecipitated by antibody HMA-
31 were observed on the gels under non-reducing conditions,
suggesting that these components are not disulphide-linked
(not illustrated). Furthermore, epitopes recognised by these
and previously generated antibodies are not similar as sug-
gested by the immunocompetition experiments (Table III).
Finally, concurrent to the observation of elevated levels of
cellular antigens recognised by allogenic immune response,
elevated expression of several cellular oncogenes has been
described in patients with metastatic mammary carcinomas
(Slamon et al., 1984) and other malignant diseases (Erikson
et al., 1983; Gallick et al., 1985; Giallongo et al., 1983;
Heighway & Hasleton, 1986; Slamon et al., 1984; Stewart et
al., 1986). It is conceivable that the antigens detected in
autologous malignant cells by human monoclonal antibodies
may be related to growth factors or their receptors, some of
which have been found to be oncogene products. Human
monoclonal antibodies may, therefore, be useful probes to
determine functional aspects of these antigens. Furthermore,
these antibodies, compared with xenogenic monoclonal anti-
bodies, are potentially useful probes for radiolocalisation
and immunotherapy of patients with mammary carcinomas.
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